Phentermine is FDA-approved only for short-term use, defined on the label as “a few weeks.” But in practice, many doctors prescribe it for months or even longer, and a growing body of evidence suggests that year-long use can be both effective and reasonably safe for certain patients. The gap between the official label and real-world prescribing is one of the most common points of confusion around this medication.
What the FDA Label Actually Says
The FDA approved phentermine as a short-term adjunct to diet and exercise, specifically for patients with a BMI of 30 or higher (or 27 with conditions like high blood pressure or diabetes). The label limits use to “a few weeks,” which generally means about 12 weeks. It’s classified as a Schedule IV controlled substance, putting it in the same regulatory category as drugs like benzodiazepines, which have a recognized but relatively low potential for misuse.
That short-term label dates back decades and has never been updated with modern long-term trial data. This doesn’t mean year-long use is banned. Doctors can and do prescribe it off-label for longer periods based on their clinical judgment and newer evidence. Phentermine remains the most commonly prescribed anti-obesity medication in the United States, and much of that prescribing extends well beyond 12 weeks.
What Happens When People Take It for a Year
A large study using electronic health records found that patients who used phentermine continuously for more than 12 months lost 7.4% more body weight at the 24-month mark compared to short-term users. The rate of cardiovascular events or death was very low (0.3%), with no significant difference between long-term and short-term groups. The researchers concluded that longer use was associated with greater weight loss without increased cardiovascular risk in otherwise low-risk individuals.
On average, phentermine produces about a 3.6% reduction in total body weight. That number comes from pooled data and includes people who respond well and those who don’t. For individual patients who respond strongly, the losses can be considerably larger, particularly when combined with diet changes and physical activity.
Tolerance Is Common but Not Universal
One of the biggest practical concerns with year-long use is tolerance, the gradual fading of phentermine’s appetite-suppressing effect. In one study of 148 patients, about two-thirds developed some degree of tolerance over six months. Roughly 25% experienced it early (within the first three months), while 41% developed it later (between months four and six). The remaining third showed no tolerance at all.
Timing matters. Early tolerance tends to be more damaging to outcomes. Patients who developed tolerance in the first two to three months and had lost less than 3 kg (about 6.5 pounds) in month one rarely achieved meaningful weight loss by month six. But patients who developed tolerance later, after already losing significant weight, still ended up with strong results. Those who never developed tolerance lost an average of about 15% of their body weight over six months.
A practical takeaway: if phentermine stops working for you very early and you haven’t lost much weight, continuing it for a full year is unlikely to help. If it works well for the first several months and then plateaus, you may still be getting meaningful benefit from the weight already lost and the habits you’ve built.
The Heart Valve Concern Is Mostly Historical
Phentermine carries a reputation for heart problems, but this stems almost entirely from the “fen-phen” era of the 1990s, when it was commonly paired with fenfluramine. That combination caused heart valve disease and pulmonary hypertension, and fenfluramine was pulled from the market in 1997. Of 113 confirmed cases of heart valve disease from that period, 79% involved the fenfluramine-phentermine combination. Zero cases were reported with phentermine used alone.
Only two isolated case reports have ever linked phentermine monotherapy to valve problems or pulmonary hypertension, and both patients had multiple pre-existing conditions that made it impossible to attribute the problems to the drug. In long-term observational data, patients on phentermine for an average of 92 weeks (nearly two years) showed no significant increase in heart rate and actually had reductions in blood pressure similar to those seen with weight loss from dieting alone.
Addiction Risk Is Lower Than You’d Expect
Because phentermine is chemically related to amphetamine and classified as a controlled substance, many people worry about becoming dependent on it. A study of 269 patients directly investigated this question, including 117 people who had taken phentermine long-term (ranging from about one year to over 21 years) at doses sometimes well above the standard recommendation.
None of the long-term patients met criteria for phentermine abuse or psychological dependence. Craving scores were low across the board. When patients stopped the drug abruptly, they did not experience amphetamine-like withdrawal symptoms. The main thing people noticed after stopping was increased hunger, which reflects the loss of appetite suppression rather than a withdrawal syndrome. This held true even for patients who had been on the medication for over two decades.
What Your Doctor Will Monitor
If your doctor agrees to prescribe phentermine beyond the standard 12 weeks, expect regular check-ins focused on blood pressure and heart rate. Since phentermine is a stimulant, these are the most relevant safety markers. Short-term studies have generally shown stable or even improved blood pressure during treatment, likely because the weight loss itself lowers blood pressure. But individual responses vary, and someone whose blood pressure creeps up on phentermine would likely need to stop.
Your doctor will also track your weight loss trajectory. Professional guidelines from organizations like the American Gastroenterological Association acknowledge that sympathomimetic amines like phentermine are “often used for longer periods” despite the short-term label. But continued prescribing typically depends on demonstrating ongoing benefit. If you’ve plateaued completely and the drug isn’t helping you maintain losses, there’s little reason to continue.
FDA-Approved Alternatives for Longer Use
If you want something explicitly approved for chronic use, phentermine-topiramate extended release (sold as Qsymia) is one option. It combines a lower dose of phentermine with topiramate, a medication originally used for seizures that also reduces appetite. This combination is FDA-approved for long-term treatment without the “few weeks” restriction. However, no head-to-head studies have compared it directly with phentermine alone for efficacy or safety. Newer injectable medications like semaglutide and tirzepatide are also approved for ongoing use and tend to produce larger weight losses, though they come with their own side effect profiles and significantly higher costs.
For many patients, phentermine’s appeal is that it’s inexpensive, widely available, and has decades of real-world safety data. Taking it for a year falls outside the FDA label but within the bounds of what many obesity medicine specialists consider reasonable, particularly for patients who are responding well, tolerating it without cardiovascular effects, and being monitored regularly.